8q24 copy number gains and expression of the C-MYC mRNA stabilizing protein CRD-BP in primary breast carcinomas

• Tipo: Artigo em Revista Científica Internacional
• Data: 2003

Autores

Ioannidis, P (Autor) Outra; Mahaira, L (Autor) Outra; Papadopoulou, A (Autor) Outra; Manuel R Teixeira (Autor) ICBAS; Heim, S (Autor) Outra; Andersen, JA (Autor) Outra; Evangelou, E (Autor) Outra; Dafni, U (Autor) Outra; Pandis, N (Autor) Outra; Trangas, T (Autor) Outra

Revista

Título: International Journal of Cancer

Vol. 104

Páginas: 54-59

ISSN: 0020-7136

Editora: Wiley-Blackwell

Indexação

ISI Web of Knowledge - 47 Citações

Scopus - 48 Citações

Outras Informações

ID Authenticus: P-000-HD6

DOI: 10.1002/ijc.10794

Abstract (EN): The coding region determinant binding protein (CRD-BP) was isolated by virtue of its high affinity to the c-myc mRNA coding region stability determinant and shown to shield this message from nucleolytic attack, prolonging its half -life. CRD-BP is normally expressed during fetal life but is also activated de novo, in tumors. Considering that aberrant CRD-BP expression may represent an additional mechanism interfering with c-myc regulation, we screened I 18 primary breast carcinomas for CRD-BP expression, 60 of which had also been analyzed by comparative genomic hybridization (CGH). Copy number gains encompassing 8q24, the chromosome band that contains the c-myc locus, were detected in 48.3% (29/60) of tumors, whereas gains involving band 17q21, which contains the CRD-BP locus, were observed in 18.3% (11/60) of tumors. CRD-BP expression was detected in 58.5% (69/118) of tumors, implying mechanisms of activation alternative to gene amplification. Altogether, some 75% of the tumors had alterations pertaining to c-myc since they either harbored 8q24 gains and/or expressed CRD-BP. Significant associations were detected between CRD-BP expression and the absence of estrogen receptors (p = 0.005) and between the presence of 8q24 gains and an increased number of genomic changes as measured by CGH (p = 0.0017). Tumors were divided into 4 groups according to CRD-SP expression and 8q24 gains. The odds for tumors having both characteristics to be classified as poorly differentiated (grade III vs. grade I and II) were 19.6 times the corresponding odds for tumors neither expressing CRD-BP nor harboring 8q24 gains. For tumors either harboring 8q24 gains only or expressing CRD-BP alone, the corresponding odds were 6.4 and 3, respectively. (C) 2002 Wiley-Liss, Inc.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 6